A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohns Disease
A study for patients with Crohn's Disease using study drug Mongersen
Sponsor: Celgene
Enrolling: Male and Female Patients
IRB Number: AAAQ6925
U.S. Govt. ID: NCT02641392
Contact: Simon Lichtiger: 212-305-1021 / sl3687@cumc.columbia.edu
Additional Study Information: The purpose of this clinical research study is to test the effects of an investigational (being tested) study medication, GED-0301, in order to find out if GED-0301 can or cannot improve the symptoms of Crohns disease. The study will test 2 doses of GED-0301 compared to placebo. The placebo is a dummy pill that contains no study medication (or GED-0301), but looks exactly like the study medication tablet. This study will test how well your body tolerates GED- 0301 and the effect that GED-0301 has on the symptoms of your Crohns disease. This is a phase 3 study, and it means that the investigational study medication has been tested for safety and is now being tested in a larger number of patients.
This study is closed
Simon Lichtiger, MD
Do You Qualify?
Have you been diagnosed with Crohn's Disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Simon Lichtiger